Clinical trials: Lymphoblastic Leukemia Acute
Lymphoblastic Lymphoma
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
- Trial name
- NCT00187122
- Testing
- Vincristine, Radiation Therapy, Daunomycin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia
Vitamin D and Methotrexate Adverse Effects
Since methotrexate toxicity represents a major problem in patients treating with cancer and there are few studies about the role of vitamin D in the pathogenesis of this toxicity, so the aim of the present study is investigation…
- Trial name
- NCT04488237
- Testing
- Vitamin D
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Osteonecrosis
The British Osteonecrosis Study
The aim of this research is to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma within the UK.
- Trial name
- BONES (NCT02598401)
- Testing
- observation
- Where
- 4 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Leeds
Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL)
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
This was a Retrospective cohort study based on the PMSI data source
- Trial name
- NCT05349201
- Testing
- KYMRIAH, YESCARTA
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Study of Out of Specification for Tisagenlecleucel
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved…
- Trial name
- NCT04094311
- Testing
- CTL019
- Where
- 55 sites in Canada, Japan
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive
- Trial name
- NCT00390793
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell…
- Conditions
- Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma
- Trial name
- NCT02112916
- Testing
- Bortezomib, Cyclophosphamide, Cytarabine
- Where
- 212 sites in United States, Australia and 2 more
- Volunteers
- 847 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT02933333
- Testing
- GM-CSF, G-CSF, GM-CSF and G-CSF
- Where
- 7 sites in China
- Volunteers
- 405 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05290155
- Testing
- anti-CD7 CAR-T cells
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00036738
- Testing
- Cyclosporine, Dasatinib, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
- Trial name
- NCT01685021
- Testing
- MOR00208 (formerly Xmab5574)
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- MorphoSys AG
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute…
- Trial name
- NCT04684147
- Testing
- single dose of CNCT19
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Juventas Cell Therapy Ltd.
Leukemia
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002785
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- 33 sites in United States, Australia and 1 more
- Sponsor
- Children's Oncology Group
Leukemia
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01505699
- Testing
- RNA analysis, cytogenetic analysis, microarray analysis
- Volunteers
- 186 people
- Sponsor
- Eastern Cooperative Oncology Group
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen…
- Conditions
- Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Bilinear Leukemia
- Trial name
- NCT06756152
- Testing
- Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia
Clinical Significance of Occult Central Nervous System Localization
In acute lymphoblastic leukemia (ALL), the occult central nervous system (CNS) involvement appears to be associated with poor prognosis. Flow cytometry (FCM) allows detection of occult CNS localization.
- Trial name
- NCT05772000
- Testing
- cerebrospinal fluids exams
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Rome Tor Vergata
Acute Lymphoblastic Leukemia
Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children.
Acute lymphoblastic leukemia is the most common malignancy of the child. Current therapeutic strategies allow healing of over 80% of children. However these treatments are associated with toxicity, with a mortality of 1-2%.
- Trial name
- THROMBLEUKEMIA (NCT02862652)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 24 people
- Sponsor
- CHU de Reims
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory…
- Conditions
- Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL
- Trial name
- ACIT001/EXC002 (NCT03938987)
- Testing
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
- Where
- 6 sites in Canada
- Volunteers
- 63 people
- Sponsor
- University of Alberta
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00006473
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.